BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Becotatug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Becotatug\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06380348-2224@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Becotatug: Phase 3 readout est. (NCT06380348)
DESCRIPTION:Becotatug\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JMT10
 1 in Combination With Osimertinib\, Versus Cisplatin-pemetrexed in Partici
 pants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCL
 C) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mu
 tations\nEstimated primary completion: 26 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/becotatug#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06380348
URL:https://assetmemo.bio/drug/becotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134205-2224@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Becotatug: Phase 3 readout est. (NCT07134205)
DESCRIPTION:Becotatug\, phase 3\, Colorectal Cancer.\nStudy: The Study of J
 MT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Co
 lorectal Cancer\nEstimated primary completion: 1 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/becotatug#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07134205
URL:https://assetmemo.bio/drug/becotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989671-2224@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Becotatug: Phase 2 readout est. (NCT06989671)
DESCRIPTION:Becotatug\, phase 2.\nStudy: SYS6002 Plus JMT101 and Enlonstoba
 rt Injection in Participants With HNSCC\nEstimated primary completion: 30 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/becota
 tug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06989671
URL:https://assetmemo.bio/drug/becotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
